Abilify Asimtufii® safety profile: real-world experience

Join Dr Ilan Melnick as he discusses his clinical experience of the Abilify Asimtufii® safety profile compared with the published pharmacokinetic study.

The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.

Page: AU-ABAS-0064. July 2025. Copy: AU-ABAS-0054. June 2025. Video: AU-ABAS-0050. June 2025.

  • Body

    Abilify Asimtufii PBS Information: Authority required (STREAMLINED) Code: 16456 for Schizophrenia. This product is not listed on the PBS for the treatment of Bipolar I disorder

  • Body

    Please review Approved Product Information before prescribing. Product Information is available here or by calling Lundbeck on 1300 721 277

    Abilify Asimtufii® is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Level 2/9 Help St, Chatswood NSW 2067, Abilify Asimtufii® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Ltd.

    .

Related